Mohammad Moeini

Hematologist and Medical Oncologist

[Mohammad Moeini @mmoeini92]

@nobleisawinner 16

[Boost Daily @BoostDaily_]

These knots can be absolute lifesavers when things get tough 🪢💪

Watch till the end…

[Untold Secrets @RealGemsfinder]

wish I could do half of these time savers

[Mohammad Moeini @mmoeini92]

@irancell به نظرم مهمتر از esim شما باید بیشتر تمرکزتون روی گسترش دامنه خدماتتون در سایر نقاط دنیا و پوشش رومینگتون باشه.
من در کشورهای غیر همسایه با سیم کارت ایرانسل به هیچ اپراتوری نمی تونم وصل بشم!!

[ASCO @ASCO]

Prepping for #ASCO25? Preview education sessions with the #ASCOEdBook. New articles publish daily, authored by meeting faculty.

Visit: https://t.co/mwcvXnpc7q

[NEJM @NEJM]

In patients with Ph-negative B-lineage ALL and no measurable residual disease (MRD) after intensive frontline treatment, consolidation therapy with blinatumomab plus chemotherapy has significantly improved survival, as compared with chemotherapy alone. This finding led to the recent (June 2024) Food and Drug Administration (@US_FDA) approval of blinatumomab for consolidation treatment in patients with CD19+, Ph-negative, B-lineage ALL, even in those who are negative for MRD. Approval of blinatumomab for the frontline treatment of Ph-positive ALL is thus eagerly awaited. In its absence, most patients worldwide are still being treated with a tyrosine kinase inhibitors (TKI) plus reduced-dose chemotherapy, followed when possible by allogeneic transplantation, which is a much more invasive approach, particularly for older patients. The figure shows the recommended approach to management of Ph-positive ALL when the required laboratory testing, at diagnosis and during clinical follow-up, as well as TKIs and blinatumomab, are all available.

Learn more in the Review Article “Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress” by Robin Foà, MD, from @SapienzaRoma: https://t.co/tox4rTRrr3

[Mohammad Moeini @mmoeini92]

@EHA_Hematology 5

[Mohammad Moeini @mmoeini92]

@sanamloghavi Ruthless beautiful (Hairy cell)

[Mohammad Moeini @mmoeini92]

@EHA_Hematology C

[Mohammad Moeini @mmoeini92]

@EHA_Hematology D

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Some light #hemepat #leusm reading for your Sunday AM. We hope you find this helpful.
https://t.co/PE6Wiymf4n
@BloodReviews w/ @CLachowiez and Daniel Chandra

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

T cell lymphoma tx is a major unmet need in #oncology
It’s astonishing that 4 all the progress made in understanding the pathogenesis (and classification) of PTCL, treatment options are still so limited. To CHOP or not to CHOP
Slide by Dr. S Horwitz @MSKCancerCenter #SH23

[Mohammad Moeini @mmoeini92]

@lbsmithmd ATLL

[Mohammad Moeini @mmoeini92]

@blood_academy Aml m4

[Mohammad Moeini @mmoeini92]

@EHA_Hematology B

[Mohammad Moeini @mmoeini92]

@EHA_Hematology B

[Mohammad Moeini @mmoeini92]

My first year of presence in Tweeter.
✋🏼😉

[ASCO @ASCO]

.@CNN covers study presented at #ASCO23 (LBA500) that a drug used in the early stage of HR+/HER2- breast cancer significantly reduced the risk of the cancer returning after treatment: https://t.co/1O9DvUuyho @jechristensen #bcsm

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Thrilled to share our comprehensive guide on using #flowcytometry in the Dx of chronic myeloid neoplasms & post-AML clonal hematopoiesis. Co-authored w/the fabulous ⁦@SibaElHussein⁩
full text and schematics👇🏻#hemepath #mdssm ⁦@ElsevierNews⁩ https://t.co/L2RjHj58yF

[Mohammad Moeini @mmoeini92]

@sanamloghavi A cruel beauty…